心肌梗死合并贫血的限制性与开放性输血策略
本研究为3期干预性试验,纳入心肌梗死且血红蛋白<10 g/dL的患者,随机分为限制性输血策略(血红蛋白阈值7或8 g/dL)或开放性输血策略(血红蛋白<10 g/dL)。主要终点为30天心肌梗死或死亡复合终点。限制性组主要终点事件发生率16.9%(295/1749),开放性组14.5%(255/1755),风险比1.15(95%CI 0.99-1.34;P=0.07),差异未达统计学显著。结论认为开放性输血策略未显著降低30天心梗复发或死亡风险,但不能排除限制性策略的潜在危害。
要点
- 急性心肌梗死伴贫血(血红蛋白<10 g/dL)患者中,开放性输血策略(阈值<10 g/dL)较限制性策略(阈值7或8 g/dL)未显著降低30天心梗或死亡复合终点(16.9% vs 14.5%,RR 1.15;95%CI 0.99-1.34;P=0.07)。
- 限制性组平均输血红细胞单位为0.7±1.6,开放性组为2.5±2.3;随机化后第1至3天限制性组平均血红蛋白水平较开放性组低1.3至1.6 g/dL。
- 30天死亡:限制性组9.9% vs 开放性组8.3%(RR 1.19;95%CI 0.96-1.47);再发心肌梗死:限制性组8.5% vs 开放性组7.2%(RR 1.19;95%CI 0.94-1.49)。
- 作者结论认为,开放性输血策略未显著降低30天心梗复发或死亡风险,但不能排除限制性输血策略的潜在危害。
适用人群与场景
- 心肌梗死且血红蛋白水平低于10 g/dL的患者。
诊断标准与关键阈值
- 限制性输血策略:血红蛋白阈值7或8 g/dL时输血;开放性输血策略:血红蛋白阈值<10 g/dL时输血。
研究设计与关键结果
- 3期干预性试验,共3504例患者纳入主要分析;随机分为限制性输血策略(血红蛋白阈值7或8 g/dL)或开放性输血策略(血红蛋白阈值<10 g/dL)。
- 主要终点(30天心肌梗死或死亡复合终点):限制性组295/1749例(16.9%) vs 开放性组255/1755例(14.5%),风险比(多重插补模型)1.15;95%CI 0.99-1.34;P=0.07。
- 30天死亡:限制性组9.9% vs 开放性组8.3%,风险比1.19;95%CI 0.96-1.47。
- 30天再发心肌梗死:限制性组8.5% vs 开放性组7.2%,风险比1.19;95%CI 0.94-1.49。
- 平均输血红细胞单位数:限制性组0.7±1.6 vs 开放性组2.5±2.3。
- 随机化后第1至3天,限制性组平均血红蛋白水平较开放性组低1.3至1.6 g/dL。
证据类型、等级与局限
- 证据类型:3期干预性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急性心肌梗死伴贫血(血红蛋白<10 g/dL)患者中,开放性输血策略(阈值<10 g/dL)未显著降低30天心梗复发或死亡风险,但不能排除限制性输血策略的潜在危害(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A strategy of administering a transfusion only when the hemoglobin level falls below 7 or 8 g per deciliter has been widely adopted. However, patients with acute myocardial infarction may benefit from a higher hemoglobin level.
METHODS: In this phase 3, interventional trial, we randomly assigned patients with myocardial infarction and a hemoglobin level of less than 10 g per deciliter to a restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g per deciliter) or a liberal transfusion strategy (hemoglobin cutoff, <10 g per deciliter). The primary outcome was a composite of myocardial infarction or death at 30 days.
RESULTS: A total of 3504 patients were included in the primary analysis. The mean (±SD) number of red-cell units that were transfused was 0.7±1.6 in the restrictive-strategy group and 2.5±2.3 in the liberal-strategy group. The mean hemoglobin level was 1.3 to 1.6 g per deciliter lower in the restrictive-strategy group than in the liberal-strategy group on days 1 to 3 after randomization. A primary-outcome event occurred in 295 of 1749 patients (16.9%) in the restrictive-strategy group and in 255 of 1755 patients (14.5%) in the liberal-strategy group (risk ratio modeled with multiple imputation for incomplete follow-up, 1.15; 95% confidence interval [CI], 0.99 to 1.34; P = 0.07). Death occurred in 9.9% of the patients with the restrictive strategy and in 8.3% of the patients with the liberal strategy (risk ratio, 1.19; 95% CI, 0.96 to 1.47); myocardial infarction occurred in 8.5% and 7.2% of the patients, respectively (risk ratio, 1.19; 95% CI, 0.94 to 1.49).
CONCLUSIONS: In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days. However, potential harms of a restrictive transfusion strategy cannot be excluded. (Funded by the National Heart, Lung, and Blood Institute and others; MINT ClinicalTrials.gov number, NCT02981407.).
参考来源
- Carson JL, Brooks MM, Hébert PC, et al. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia. N Engl J Med. 2023. PMID: 37952133. doi:10.1056/NEJMoa2307983
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。